Qureator is proud to be featured in a recent update from our collaborator, Professor Jonathan Sexton of the University of Michigan, highlighting the use of our Curiochip™ microphysiologic system in a cutting-edge platform for predicting drug-induced liver injury (DILI).
By integrating iPSC-engineered liver cells, high-content imaging from Yokogawa CQ1, and Qureator’s innovative microphysiologic technology, the system enables higher throughput, longer-term studies, and clinically relevant drug exposure—critical for mechanistic insight into liver toxicity.
This collaboration demonstrates the power of combining robust human-relevant models with precision imaging and biomarker analysis to better understand and mitigate DILI risks in drug development.
We’re honored to support this impactful work and excited to push the boundaries of predictive toxicology together.